– USA, FL – AzurRx BioPharma, Inc. (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately, increasing the Board to seven members.
“Adding an individual of Terry’s talent and extensive executive experience to AzurRx’s Board of Directors is an achievement for our company and our shareholders,” said James Sapirstein, Chairman, President and CEO. “Terry brings to AzurRx unrivaled financial and operational experience, which will be critical to our growth and long-term success. On behalf of the Board, I am pleased to welcome Terry to AzurRx and look forward to benefitting from her knowledge and expertise.”
About Terry Coelho
Ms. Coelho currently serves as the EVP and CFO at BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior-level financial and operational positions at both emerging and publicly-traded, global companies, highlighted by tenures with leading global organizations including Novartis Pharmaceuticals, Mars, Incorporated, Sealed Air Corporation, and Diversey, Inc.
Ms. Coelho joined BioDelivery Sciences in January 2019 and previously served as the CFO and Treasurer. Before her tenure at BioDelivery Sciences, Ms. Coelho served as CFO and Treasurer at Balchem Corporation (NASDAQ: BCPC) from October 2017 to October 2018. From September 2017 to October 2017, she served as COO for Diversey, Inc., a multibillion-dollar global private equity carve-out from Sealed Air, and held senior finance positions at Diversey Care from October 2014 through August 2017, including as CFO for Diversey Care. Ms. Coelho has also served in other senior finance leadership roles, including Global Head of Oncology Development Finance at Novartis from 2007 to 2014. Ms. Coelho earned an MBA in Finance from IBMEC in Brazil and Bachelor of Arts degrees in Economics and International Relations, summa cum laude, from The American University School of International Service in Washington, DC. She has led Women’s Networking ERGs and is a founding Steering Committee Member of the CFO Leadership Council – Charlotte chapter.
“I am honored to be joining the Board of AzurRx BioPharma,” said Ms. Coelho. “My goal is to utilize my extensive financial background in both pharma and other industries to help AzurRx achieve its full growth potential. Both shareholders and patients have the opportunity to benefit from what I believe to be important therapeutic advancements being developed by AzurRx for the treatment of COVID-19 related GI disease, Immune Checkpoint inhibitor-associated colitis, and exocrine pancreatic insufficiency.”
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. The Company has a pipeline of two gut-restricted GI assets in three clinical indications. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. AzurRx is also advancing two clinical programs using proprietary formulations of niclosamide, a small molecule with anti-viral and anti-inflammatory properties: FW-1022, for COVID-19 gastrointestinal infections and FW-420, for Grade 1 and Grade 2 Immune Checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients. The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California.
For more information: https://www.azurrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
